- HEXO (HEXO) and Entourage Health (ENTG) have signed a three-year supply agreement
- HEXO will provide Entourage with bulk dried cannabis and soft gel capsules to be marketed alongside Entourage’s family of brands
- The partnership will allow HEXO to better serve medical patients through Entourage’s established channels, while Entourage will benefit from HEXO’s production capabilities to meet anticipated short-term demand
- HEXO is an award-winning producer of innovative cannabis products for the global market
- Entourage Health produces and distributes cannabis products for both the medical and adult-use markets
- HEXO (HEXO) is unchanged, trading at $0.245 per share
- Entourage (ENTG) is up by 14.29 per cent, trading at $0.04 per share
HEXO (HEXO) and Entourage Health (ENTG) have signed a three-year supply agreement.
HEXO will provide Entourage with bulk-dried cannabis and soft gel capsules to be marketed alongside Entourage’s family of brands.
HEXO-branded products – including Redecan’s Gems, Redebles and Redees – will expand Entourage’s premium offerings to patients of its Starseed Medicinal and Syndicate marketplaces.
The partnership will allow HEXO to better serve medical patients through Entourage’s established channels, while Entourage will benefit from HEXO’s production capabilities to meet anticipated short-term demand.
The agreement can be renewed for an additional three years at Entourage’s election and provides for minimum annual purchase commitments by Entourage with year-over-year increases. It also includes exclusivity for HEXO in supplying the specified products.
“This relationship with Entourage not only complements our growing health and wellness portfolio but also accelerates our ability to grow the business and deliver premium cannabis products to more Canadians,” stated Charlie Bowman, HEXO’s CEO.
“We are excited about the opportunities this new relationship with HEXO brings to the medical cannabis market,” added George Scorsis, Entourage’s CEO and Executive Chairman. “Leveraging HEXO’s cultivation capabilities will allow us to more comprehensively service all our markets and provide patients and consumers with a premium, consistent supply of cannabis.”
HEXO is an award-winning producer of innovative cannabis products for the global market.
Entourage Health produces and distributes cannabis products for both the medical and adult-use markets.
HEXO (HEXO) is unchanged, trading at $0.245 per share as of 11:12 am ET.
Entourage (ENTG) is up by 14.29 per cent, trading at $0.04 per share as of 10:36 am ET.
